1Caner B,Kitapcl M,Unlu M,et al.Technetium-99m-MIBI uptake in benign and malignant bone lesions:a comparative study with technetium-99m-MDP.J Nucl Med,1992,33:319-324.
2Ozcan Z,Burak Z,Erinc R,et al.Correlation of 99TCm-sestamibi uptake with blood-pool and osseous phase TC -MDP uptake in malignant bone and soft-tissue tumours.Nucl Med Commun,2001,22:679-683.
3Moretti JL,Azaloux H,Boisseron D,et al.Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression.Eur J Nucl Med,1996,23:980-986.
4Kostakoglu L,Elahi N,Kiratli P,et al.Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors.J Nucl Med,1997,38:1003-1008.
5Varrella P,Lastoria S,Vergara E,et al.Tc-99mMIBI scintimammography for monitoring tumour response in patients with advanced breast cancer.J Nucl Med,1995,36:193-195.
6Taki J,Sumiya H,Asada N,et al.Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy.JNuclMed,1998,39:1179-1184.
7Burak Z,Moretti JL,Ersoy O,et al.99TCm-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression.J Nucl Med,2003,44:1394-1401.
8Soderlund V,Larsson SA,Bauer HC,et al.Use of 99TCm-MIBI scintigraphy in the evaluation of the response of osteosarcoma to chemotherapy.Eur J Nucl Med,1997,24:511-515.
9Punyaratabandhu T,Wittayawongsaruji S,Rajchadara S,et al.The correlation of 99TCmMIBI scintigraphy and histological response in determining the percentage of tumor necrosis in osteosarcoma after preoperative chemotherapy.J Med Assoc Thai,2005,88(Suppl3):S53-62.
10Gorlick R,Liao AC,Antonescu C,et al.Lack of correlation of functional scintigraphy with (99m) technetium-methoxyisobutylisonitrile with histological necrosis following induction chemotherapy or measures of P-glycoprotein expression in high-grade osteosarcoma.Clin Cancer Res,2001,7:3065-3070.
